Vadastuximab disitamab vedotin antibody-drug conjugate representing a significant advancement in the approach of acute myeloid leukemia (AML). This groundbreaking therapy specifically targets CD33, a antigen https://bookmark-template.com/story28569723/vadastuximab-a-deep-dive-into-cd33-targeted-therapy